Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
GCAN needs to find a way to attach the tab to a share certificate. It is the only way they will get 10 million sold.
I have a feeling that 10 million is just the beginning. GL
It is the responsibility of the shareholders to hold management responsible for their performance. So far the gcan leadership and their performance has not produced anything of value. If Gcan changes their performance and results I am sure the demeanor of many investors on this board will change. The results of gcan speak poorly of it's management. Seems to be interest and volume, hopefully things are changing for the better.
It looks like he had absolutely nothing better to do during the course of his day. He responded with in minutes. That can be looked at in 2 ways. ie 1. This CEO is on top of it or 2. This CEO is sitting on his cpu playing solitaire praying for an email to answer to give himself something to do. Take your pick. I am hoping for option 1.
Yes, It seems to be heading the right direction. GCAN needs to step it up and let us know how and when the company can expect payment from symtomax.
Good afternoon xxxxxxxxxxx,
Thank you for your email enquiry about GCAN. Symtomax have a JV partnership in place with GCAN to be distributor of their oral patch which we have white labelled and will be launching as the Symtomax Oral Tab. Our agreement terms are strictly private and confidential between our companies. However I would urge you as an investor of GCAN and not Symtomax to contact them and direct any questions you have to them. Symtomax have an ongoing PR campaign to promote this product and we believe this will be hugely successful which I presume all share holders of GCAN will benefit from, however that a conversation you must have with them. Again I want to re iterate we can not disclose any sensitive corporate information which has been agreed under signed NDA.
Many thanks
Paul Segal
Chairman & Co-Founder
Praça Bom Sucesso, Edifício Península nº127/131. 8ºandar, Escritório 801, 4150-146 Porto, Portugal
phone: +351 937019489
email: paul@symtomax.com
web: www.symtomax.com
I just sent the to symptomax.
How is GCAN being compensated by Symtomax and when do you expect to be paying them?Thank you,
I need to know 1 thing. How is GCAN being paid. That is all.
I would not worry about them covering expenses they have plenty of shares to offer, and there always seems to be an endless supply.
That is the question we all need answered. How and what are we paid for gcan process. As far as additional companies symtomax would be crazy if the did not have gcan sign a no compete contract to avoid direct competition.
The plot has thickened. If that is the case I wonder how long GCAN sticks around with Symtomax. It seems to be the only donkey we have hitched our cart too.
GCAN posted revenue at $2600. 0 LOI's have produced $$. Either the IP/gcan process is bad or the LOI companies are worthless. Take your pick.
Here are the facts. Price is .027. There is an endless supply of shares. GCAN has 0 income. Chances to get to 1 cent is real. Good luck.
I am trying to do the math. There is no x's or Y's to enter in to the equation.
Oraltabs.com means nothing to gcan current stock price. It has been stated that our relationship is only one of IP and or the GCAN patented technology of a fully dissolving patch. So far GCAN has been paid $2,600 for consulting. It does not matter what symtomax is selling. It only matters to us if they are paying gcan for the IP. Is it per patch produced? Per patch sold? Is it a percent of profit. Are we paid by flat fee? How is gcan monetizing its IP. GCAN stockholders should know this. It does no good to say we are selling our IP, but have no idea how we are getting paid for what we bringing to the table.
Supply is endless. Demand is little to none. Price is in a free fall.
It is the same gcan story being written each day. High volume and the sp goes down. Low volume and the sp goes down. I would guess that the supply is very high at this point.
That would be a great place to start. Hopefully trading starts soon.
Who issues the shares to Emit and how many does it add to the float?
I am most interested in what the pps is on the first day of trading for trnf. With the #'s that were posted and the amount of shares it could be a crazy first day.
You are correct. TNRF might just start out like a rocket. The current results of the company are unbelievable and it is not even trading. Let's hope it is not another one of the p&d's.
Just so I understand this, the strategy that is now going to make gcan successful is being a "clean" shell company? If that is the case, the expectation has certainly changed over the last 6 months.
That was quick.
Investor Relations
10:58 AM (1 minute ago)
to me
No issue that we are aware of. Just waiting on SEC approval. It has taken much longer than we expected
Sent new email to TNRX asking what is taking so long with TNRF. They stated 1-2 weeks on 12/18. It is now 1/7 and past the time stated. I will post response.
I am sure there are plenty of shares to buy. Based on past performance if a few million shares trade or are unloaded by the company to pay for the next trade show booth we should see .025. Party at the GCAN booth. Free skunk and LOI's!!!
Correct. The results are in. 0 product. I will phrase properly. No products with GCAN technology has been sold for profit to anyone, anywhere, at any time. $2600 Consulting fee is the GCAN total revenue. Looking forward to the technology actually being used by a real company that produces real products. So far we have a bunch of loi's with 0 actual results, setting a booth up at an expo or two and selling a couple million shares to pay for a couple days of partying does not make gcan a success. It will go something like this. Come over to gcan's table drop your card in the fish bowl and we will sign a LOI with you. That action will get your name on globenwire for a day! You may even be on the break out board for 2 hours, where all of 10 total people around the world will know you exist. Step right up, step right up, loi's are ready to be signed here.
GCAN needs to sign a letter of intent with itself to actually produce a product. That would set the investment world on FIRE. Share price would be sure to hit that magic #, whatever that # is!
The first payment is due in February. Gcan has $2,600 for consulting services. The only other money they have collected to pay off anything has to have come from selling shares. It will be interesting to see what the share count is on March 1, 2020.
I did not buy it. They were given to me.
There will be no change in anything until GCAN provides verified results. The company is currently in the same position as many MJ start up companies that talk about products that would be nice to have and to sell. The only problem is that most have products that are never produced or sold. The dot.com boom/bust came and went now the MJ boom/bust seems to be happening and GCAN seems to be a little late to the party, with a product that can't get produced. Is symtomax our savior? I doubt it, if gcan technology was as good as advertised we would already be producing the patch and selling it. The dream team would have already found a way to get a product to market with out sharing the $$, people are greedy.
I enjoyed my first BRFH single serve pack this week. They were excellent and process was very easy. I had Mango and berry and used a vitamix commercial blender at home and the product was excellent. I do think they could make the pack a little smaller though and price to sell for the same amount. I shared each smoothie and there was enough for 2 in each bag.
Interesting how reality trumps dreams and power point presentations of no results. Now carry on with share structure debate.
Apparently the oral eluting patch has turned in to a tab like everyone else's. The issue for gcan is that everyone else's patch is already being sold. What incentive does person have to switch. Convincing a person that is used to a patch that they apply to the arm to put something in their mouth that may or may not leave residue, bad taste, weird feel in their mouth will not be easy. Who is suggesting it. Not the Dr. that's for sure. Again, what is GCAN getting out of this. So far $2,600, total.
This has been the issue all along. If the technology is so good why has it taken 10 years to come to market. It makes no sense. I think the previous evaluation of the patch may not have worked out in the Dr's favor, which is why it was moved to the unregulated weed arena. The price seems to have settled at around 4 cents and sadly that is what it is worth.
Another day goes by with business as usual with gcan.
No idea but based on past experiences I choose to be realistic and not overlook a companies inability to perform. It is nothing personal to anyone on this board. I am invested here but I do choose to not have my head in the sand. Gcan is on the clock for results. The only thing that will move this stock is verifiable results. Not loi’s and pipe dreams. Results.
Common sense leads me to believe they are dumping. I have a hard time believing anything else. The share price is indicative to supply and demand. Supply is wwwwwwaaaaaayyyyyyyyyyyyyy ahead of demand here.
Gcan will be paid a fee for the use of their IP/process correct? I would like to know if Gcan is paid per patch or a flat fee per year. Symtomax looks great, but they are not Gcan we need to know what they are paying Gcan. I would also like to know who paid gcan the 2,600 consulting fee. Was it Ican or Symtomax? If our consulting is only worth $2,600 that is a problem. What was Gcan actually consulted about? We can not get confused with the success of symtomax and the daily trading of gcan. Symtomax is using gcan to process patches for their success. It is not the other way around. Gcan at this time is getting 0 for their patch. I certainly hope that changes soon.
If the company is basically worth 1.4 million at the current price and the product is so unbelievable I do not understand the lack of interest in someone buying the entire company. It just does not make any sense. $$$ is everywhere. % rates are low. There is no problem borrowing $$. Stock market is on a 12 year tear. Why is there no interest in the patch that is supposed to change everything. I still think a person involved with Symtomax or Ican would be chomping at the bit to buy this company that holds the IP that Symtomax is going to be using. If no one is interested that is in the know, our IP may not be that special.
I sent email. Here is what I got back. "We internally have an independent valuation of $1 per share. The actual trading value will be set by the market. We expect trading to commence in one to two weeks."
Have a great day.